(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 775.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Oculis Holding Ag's revenue in 2026 is $355,555.On average, 12 Wall Street analysts forecast OCS's revenue for 2026 to be $347,317,825, with the lowest OCS revenue forecast at $0, and the highest OCS revenue forecast at $2,405,410,614. On average, 9 Wall Street analysts forecast OCS's revenue for 2027 to be $3,446,581,842, with the lowest OCS revenue forecast at $153,320,481, and the highest OCS revenue forecast at $12,848,412,789.
In 2028, OCS is forecast to generate $15,465,030,189 in revenue, with the lowest revenue forecast at $2,807,094,630 and the highest revenue forecast at $42,623,540,823.